Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients (An open treatment trial of NMO with MMF)

Completed

• Conditions: Neuromyelitis optica

• Registration Number: jRCTs051180080

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-12
• Study First Submitted: 2019-02-27
• Last Update Posted: 2022-03-30

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Stable Neuromyelitis Optica patients with EDSS score less than 7.0 who wish to participate in this study

Exclusion Criteria

1. Patients with infection
2. Patients with pregnancy or breast-feeding
3. Patients who take any immunosuppressant other than steroid
4. patients with severe liver or kidney dysfunction
5. patients with a history of cancer within 5 years (including carcinoma in situ)
6. In addition, patients judged inappropriate by the investigators

Study & Design

• Study Type: Interventional
• Study Design: single assignment

Primary Outcome Measures

Name	Time	Method
Steroid dose halved	1 year after starting Mycophenolate mofetil	Whether the steroid dose is halved according to the treatment protocol
No clinical relapse	1 year after starting Mycophenolate mofetil	There is no clinical relapse with this combination therapy